Clinical effect of double filtration plasmapheresis combined with glucocorticoid and immunosuppressant in treatment of children with severe Henoch-Schönlein purpura nephritis.
- Author:
Na LIU
1
;
Zhong-Zheng MA
;
Hui-Fang YAN
;
Qiong LI
;
Xiao-Qian LYU
;
Wei-Li KANG
;
Zhan-Ru YIN
Author Information
1. Department of Pediatrics, Harrison International Peace Hospital, Hengshui, Hebei 053000, China. kwlpsydbyly@163.com.
- Publication Type:Journal Article
- MeSH:
Child;
Glucocorticoids;
Humans;
Immunosuppressive Agents;
Nephritis;
Plasmapheresis;
Purpura, Schoenlein-Henoch
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(10):955-959
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical effect and safety of double filtration plasmapheresis (DFPP) combined with double pulse therapy with methylprednisolone (MP) and cyclophosphamide (CTX) in the treatment of children with severe Henoch-Schönlein purpura nephritis (HSPN).
METHODS:A total of 60 children with severe HSPN who were admitted to the hospital from January 2014 to March 2018 were enrolled and were randomly divided into an observation group and a control group (n=30 each). In addition to routine treatment, the children in the control group were given MP+CTX pulse therapy. Those in the observation group were given DFPP treatment in addition to the treatment in the control group, with three courses of treatment in total. After three courses of treatment, the two groups were compared in terms of 24-hour urinary protein, urinary microproteins, renal function parameters, adverse reactions, and clinical outcome.
RESULTS:After three courses of treatment, the observation group had significantly greater reductions in 24-hour urinary protein, urinary albumin, urinary immunoglobulin G, urinary β2-microglobulin, serum creatinine, and blood urea nitrogen than the control group (P<0.05). After the treatment ended, the observation group had a significantly shorter time to achieve remission than the control group (P<0.05). No serious adverse reactions, such as hemorrhagic cystitis, thrombocytopenia, and hemolysis, were observed, and there was no significant difference in the overall incidence rate of adverse reactions between the two groups (P>0.05).
CONCLUSIONS:Compared with MP+CTX pulse therapy alone in the treatment of severe HSPN in children, DFPP combined with MP+CTX pulse therapy can further alleviate renal injury and improve clinical outcome and does not increase the incidence rate of adverse reactions.
